0. DOCID:31947 SCORE: 0.00285880782073024DOCNO: 12073121OWNER: NLMSTATUS: MEDLINEDESCRIPTOR: ButtocksQUALIFIER: diagnosisQUALIFIER: diagnosisQUALIFIER: pathologyAUTHOR: Ik Yang IAUTHOR: Curtis W Hayes CWAUTHOR: J Sybil Biermann JSAFFILIATION: Department of Radiology, University of Michigan Health Systems, Ann Arbor, USA.PUBTYPE: Case ReportsPUBTYPE: Journal ArticleJOURNALTITLE: Skeletal radiology. COUNTRY: GermanyTITLE: Calcific tendinitis of the gluteus medius tendon with bone marrow edema mimicking metastatic disease.PUBDATE: 20020601
A case of calcific tendinitis of the gluteus medius is presented. This report describes a patient with a history of breast cancer who had the combination of amorphous calcifications in the gluteus medius tendon and the MR finding of conspicuous bone marrow edema in the adjacent greater trochanter, prompting concern for metastatic disease. We present images from radiography, bone scanning, CT, and MR imaging. The unusual combination of findings in these studies should be considered conclusive for calcific tendinitis, and should not be confused with malignancy.

1. DOCID:31598 SCORE: 0.00230998348135791DOCNO: 16382037OWNER: NLMSTATUS: In-ProcessAUTHOR: Patrick A Everley PAAUTHOR: Bruce R Zetter BRAFFILIATION: Department of Surgery, Children's Hospital / Harvard Medical School, Boston, Massachusetts 02115, USA.PUBTYPE: Journal ArticleJOURNALTITLE: Annals of the New York Academy of Sciences.COUNTRY: United StatesTITLE: Proteomics in tumor progression and metastasis.PUBDATE: 20051101
With the ultimate goal of systematically identifying and characterizing proteins within an organism, the field of proteomics has generated much excitement in the past few years. Coupled with mass spectrometry, various quantitative and functional techniques are now available that allow for large-scale analyses of proteins implicated in cancer. New techniques are just now being applied to identifying the temporal changes in protein levels associated with tumor development. This review will focus on the use and promise of proteomic technologies as they apply to the study of tumor progression and metastasis.

4. DOCID:29982 SCORE: 0.00198764060672833DOCNO: 14764990OWNER: NLMSTATUS: MEDLINEQUALIFIER: pathologyQUALIFIER: biosynthesisAUTHOR: Arun Singh AAUTHOR: William D Figg WDAFFILIATION: Howard Hughes Medical Institute, Chevy Chase, Maryland, USA.PUBTYPE: Journal ArticleJOURNALTITLE: Cancer biology & therapy. COUNTRY: United StatesTITLE: Upregulation of the androgen receptor during prostate cancer progression.PUBDATE: 20040301
The androgen receptor is one of the central factors in mediating prostate cancer progression and is an important target for treatment. Several possible mechanisms have been put forth as to how it promotes this process. In the January 2004 issue of Nature Medicine, Chen et al. report that the androgen receptor is consistently upregulated as hormone sensitive prostate cancer changes to a hormone refractory state. They also show that this change is intricately involved during the development of resistance to androgen ablation therapy.

13. DOCID:31888 SCORE: 0.001436764145959DOCNO: 15330895OWNER: NLMSTATUS: MEDLINEDESCRIPTOR: Practice GuidelinesQUALIFIER: diagnosisQUALIFIER: statistics & numerical dataQUALIFIER: diagnosisQUALIFIER: statistics & numerical dataQUALIFIER: standardsAUTHOR: Andrew D Feld ADAFFILIATION: University of Washington.PUBTYPE: Journal ArticlePUBTYPE: ReviewJOURNALTITLE: The American journal of gastroenterology. COUNTRY: United StatesTITLE: Malpractice risks associated with colon cancer and inflammatory bowel disease.PUBDATE: 20040901
Analyses of lawsuits against gastroenterologists suggest that the disorders of colon cancer and inflammatory bowel disease are among the more common disorders resulting in malpractice claims, with colon cancer suits receiving some of the highest monetary judgments. Unfortunately, that composite data does not specify the exact alleged wrongdoing, but uses global categories such as "errors of diagnosis." This review will focus on potential legal pitfalls regarding those disorders. The focus is on the legal theories, not the exact medical approach recommended, and is intended as general education, and not legal advice for any specific patient.

14. DOCID:31969 SCORE: 0.0014367633636038DOCNO: 11929036OWNER: NLMSTATUS: MEDLINEQUALIFIER: adverse effectsQUALIFIER: drug therapyQUALIFIER: etiologyAUTHOR: Munni Ray MAUTHOR: R K Marwaha RKAUTHOR: Amita Trehan AAFFILIATION: Division of Pediatric Hematology-Oncology, Advanced Pediatric Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India.PUBTYPE: Case ReportsPUBTYPE: Journal ArticleJOURNALTITLE: Indian journal of pediatrics.COUNTRY: IndiaTITLE: Chemotherapy related fatal neurotoxicity during induction in acute lymphoblastic leukemia.PUBDATE: 20020201
Neurotoxicity is a common complication during cancer chemotherapy. It is estimated that 3-10% of children with acute lymphoblastic leukemia (ALL) experience acute, transient neurotoxicity during induction chemotherapy. Fatal acute neurotoxicity is rarely encountered. Neurological evaluation of children with ALL at diagnosis and during treatment is of value in order to diagnose neurological complications early so that appropriate intervention can be adopted. This communication describes the profile of two children with unexpected, acute fatal neurologic toxicity during induction chemotherapy for ALL.